Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.64 |
| ▸ | PPARA | Q07869 | 6/20 | 0.61 |
| ▸ | PPARG | P37231 | 3/20 | 0.61 |
| ▸ | LSS | P48449 | 1/20 | 0.60 |
| ▸ | PPARD | Q03181 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11935307 | 0.84 | RORC (0.51) | EPHX2NR1H4PPARAPPARGPPARD | |
| SCHEMBL10116639 | 0.84 | PPARA (0.67) | EPHX2NR1H4PPARAPPARGLSS | |
| SCHEMBL10116353 | 0.83 | EPHX2 (0.58) | EPHX2NR1H4PPARGLMNAMAPT | |
| SCHEMBL11935291 | 0.83 | FFAR1 (0.53) | PPARAPPARGPPARDCA1CA2 | |
| SCHEMBL10114489 | 0.83 | TRPV1 (0.68) | CA1CA2MEN1MAPTKMT2A | |
| SCHEMBL13947580 | 0.78 | LSS (0.72) | EPHX2NR1H4PPARAPPARGLSS | |
| SCHEMBL12010898 | 0.78 | MAPT (0.80) | PPARALSSMAPK14CA2NAMPT | |
| SCHEMBL12619647 | 0.78 | EPHX2 (1.00) | EPHX2NR1H4PPARGCA1CA2 | |
| SCHEMBL3455877 | 0.77 | LSS (0.69) | EPHX2NR1H4PPARAPPARGLSS | |
| SCHEMBL20477562 | 0.77 | L3MBTL1 (0.69) | EPHX2PPARAPPARGLSSMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | EPHX2 2527/4885NR1H4 311/4885PPARA 1639/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | EPHX2 2306/4885NR1H4 278/4885PPARA 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.